BioSpace News Archive

Castle Creek Biosciences, Inc., a privately held, late-stage gene therapy company, announced that it has received a new investment of $75 million to support the advancement of its clinical development pipeline.

- Multiple antibodies identified that neutralize SARS-CoV-2 - Phase 1/2 clinical testing planned for this summer

Forge Therapeutics, Inc. (Forge) announced today that they have entered into a research collaboration and option agreement with Hoffmann-La Roche Ltd. (Roche) to license FG-LpxC LUNG, a novel antibiotic for the treatment of serious lung infections attributed to antibiotic-resistant Gram-negative bacteria including Pseudomonas aeruginosa.

Baril Corporation and ViruDefense, Inc. today announced that the two companies have been collaborating over the past six weeks to develop high-capacity, US-based manufacturing capabilities of surgical N95-F respirator masks combining the filtration capabilities of N95 masks with the fluid resistance of surgical masks.

Vycellix™, Inc., an immuno-discovery cell & gene therapy company, and Avectas Limited, a cell engineering technology business, today jointly announced that the companies have entered into a collaboration agreement to develop proprietary approaches for cell-based immunotherapeutic products. The companies will collaborate on the delivery of Vycellix’s novel RNA immunomodulator VY-M using Avectas’ cell

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, plans to present a corporate overview and provide a business update at the upcoming Solebury Trout Virtual Investor Conference on Tuesday, March 31, 2020 at 12:30pm EDT. A webcast of the presentation will be available in the investors section of the Company’s websit

ENHERTU ® Approved in Japan for Treatment of Patients with HER2 Positive Unresectable or Metastatic Breast Cancer Approval based on the pivotal DESTINY-Breast01 trial represents third approval ever under the conditional early approval system in Japan, and follows recent U.S. accelerated approval of ENHERTU ® ENHERTU ® represents the second innovative treatment from the oncology pipeline of Daiichi Sankyo to be approved for use in Japan in past

Name Change Emphasizes Company Vision and Mission to Combat Cancer -

DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today released the following letter from its CEO John Dobak, M.D.: We at DermTech are monitoring the COVID-19 pandemic daily. In these uncertain times, the health and safety of our employees and other stakeholders is a top priority. In an effort to limit the spread of COVID-19, we are man

A study evaluating endoscopic procedure time removing complex colorectal polyps shows superiority of DiLumen over control group. WESTPORT, Conn.--( BUSINESS WIRE )-- Connecticut-based medical device innovator Lumendi, LLC ( www.lumendi.com ) reports that its 1:1 randomized trial of the DiLumen Endolumenal Interventional Platform (EIP) successfully met the primary endpoint of an IRB-approved 200-patient prospective study. The study evaluates DiLumen’